Raven biosciences ApS Financials, key figures and credit report
Net sales 6 977.1 kDKK FY 2025 +36.9% vs 2024
EBIT margin 19.8 % FY 2025 +44.2 pp vs 2024
Net debt - 274.9 kDKK FY 2025 +92.1% vs 2024
Quick ratio 2.1 FY 2025 +0.6 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 5 956.86 | 12 670.19 | 7 055.10 | 5 095.38 | 6 977.06 |
| External services | -2 558.34 | -5 187.34 | -1 062.24 | - 980.54 | - 868.98 |
| Gross profit | 3 398.52 | 7 482.86 | 5 992.86 | 4 114.84 | 6 108.08 |
| Employee benefit expenses | -2 480.49 | -4 000.16 | -5 260.05 | -5 357.36 | -4 723.99 |
| EBIT | 918.03 | 3 482.70 | 732.81 | -1 242.52 | 1 384.08 |
| Other financial income | 183.83 | 90.68 | 103.46 | 6.10 | |
| Other financial expenses | -7.58 | - 489.59 | - 421.30 | -47.09 | -24.71 |
| Pre-tax profit | 910.45 | 3 176.94 | 402.19 | -1 186.15 | 1 365.47 |
| Income taxes | - 200.30 | - 699.38 | 27.35 | 260.95 | - 300.40 |
| Net earnings | 710.15 | 2 477.56 | 429.53 | - 925.20 | 1 065.07 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 2 077.67 | 4 688.32 | 638.34 | 941.32 | 3 068.97 |
| Current amounts owed by group member comp. | 55.55 | ||||
| Current other receivables | 199.61 | 476.15 | 524.92 | 558.47 | 2 020.15 |
| Current deferred tax assets | 27.35 | 288.30 | |||
| Short term receivables total | 2 277.28 | 5 164.47 | 1 190.60 | 1 788.09 | 5 144.68 |
| Cash and bank deposits | 709.51 | 2 774.48 | 6 094.27 | 3 490.05 | 274.90 |
| Cash and cash equivalents | 709.51 | 2 774.48 | 6 094.27 | 3 490.05 | 274.90 |
| Balance sheet total (assets) | 2 986.79 | 7 938.95 | 7 284.87 | 5 278.14 | 5 419.59 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Shares repurchased | 1 000.00 | ||||
| Retained earnings | 254.94 | 965.10 | 2 442.41 | 2 671.95 | 1 746.75 |
| Profit of the financial year | 710.15 | 2 477.56 | 429.53 | - 925.20 | 1 065.07 |
| Shareholders equity total | 1 015.09 | 3 492.66 | 3 921.95 | 1 796.75 | 2 861.82 |
| Non-current liabilities total | |||||
| Current trade creditors | 1 668.38 | 3 563.21 | 3 204.91 | 2 422.09 | 1 602.30 |
| Short-term deferred tax liabilities | 128.24 | 681.99 | |||
| Other non-interest bearing current liabilities | 175.07 | 201.09 | 158.01 | 1 059.31 | 955.47 |
| Current liabilities total | 1 971.69 | 4 446.29 | 3 362.92 | 3 481.39 | 2 557.77 |
| Balance sheet total (liabilities) | 2 986.79 | 7 938.95 | 7 284.87 | 5 278.14 | 5 419.59 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated